Earnings Bonanza: Exclusive Stock Alert Inside!

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Americans Now Favor Gold Over Stocks as an Investment Vehicle]( [See why investors are so impressed by this overlooked gold investment strategy.]( --------------------------------------------------------------- February 14, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Gold Could Be Heading for Record Highs - But How to Play It?]( to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. [See this little-known way to play in the rising gold market.]( --------------------------------------------------------------- [Agnico Eagle Mines Limited]( Symbol: [AEM]( Recent Price: $44.98 Average Analyst Price Target: $65.04 (44.60%) Market Cap: $22.24B Last Year's EPS: $0.65 Consensus EPS Forecast: $0.46 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Mike Parkin, analyst at National Bank, reiterates coverage on [Agnico Eagle Mines Limited (AEM)]( in the Basic Materials sector with a Buy rating and a price target of $61.92 (1 week ago). [TipRanks.com]( also reports that [Agnico Eagle Mines Limited]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $65.04 . The target pricing ranges from a high forecast of $71 down to a low forecast of $61. [Agnico Eagle Mines Limited (AEM)](’s last closing price was $44.98 which would put the average price target at 44.60% upside. Here are 3rd party ratings for [AEM](: - TipRanks.com: Buy - TradingView.com: Strong Sell - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Bottom 28% (181 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Fox Couldn't Air my #1 A.I. Pick - Get it Here.]( Wall Street Insider Marc Chaikin got invited onto Fox News to talk about A.I. - Here's what he couldn't say on television. [More here.]( --------------------------------------------------------------- [Ultragenyx Pharmaceutical Inc.]( Symbol: [RARE]( Recent Price: $43.98 Average Analyst Price Target: $79.75 (81.33%) Market Cap: $3.61B Last Year's EPS: $-2.25 Consensus EPS Forecast: $-2.08 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Whitney Ijem, analyst at Canaccord Genuity, reiterates coverage on [Ultragenyx Pharmaceutical Inc. (RARE)]( in the Healthcare sector with a Buy rating and a price target of $110 (1 week ago). [TipRanks.com]( also reports that [Ultragenyx Pharmaceutical Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $79.75 . The target pricing ranges from a high forecast of $82 down to a low forecast of $110. [Ultragenyx Pharmaceutical Inc. (RARE)](’s last closing price was $43.98 which would put the average price target at 81.33% upside. Here are 3rd party ratings for [RARE](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 36% (89 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Pacific Biosciences of California, Inc.]( Symbol: [PACB]( Recent Price: $6.08 Average Analyst Price Target: $13.10 (115.46%) Market Cap: $1.63B Last Year's EPS: $-0.26 Consensus EPS Forecast: $-0.3 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Daniel Brennan, analyst at TD Cowen, reiterates coverage on [Pacific Biosciences of California, Inc. (PACB)]( in the Healthcare sector with a Buy rating and a price target of $19 (2 days ago). [TipRanks.com]( also reports that [Pacific Biosciences of California, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $13.10 . The target pricing ranges from a high forecast of $8 down to a low forecast of $11. [Pacific Biosciences of California, Inc. (PACB)](’s last closing price was $6.08 which would put the average price target at 115.46% upside. Here are 3rd party ratings for [PACB](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Sell, Top 42% (106 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [#1 Stock for Energy Crisis (Buy Now for Just $8)]( the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( --------------------------------------------------------------- [Prothena Corporation plc]( Symbol: [PRTA]( Recent Price: $26.49 Average Analyst Price Target: $69.00 (160.48%) Market Cap: $1.42B Last Year's EPS: $-1.03 Consensus EPS Forecast: $-0.32 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Tazeen Ahmad, analyst at Bank of America Securities, reiterates coverage on [Prothena Corporation plc (PRTA)]( in the Healthcare sector with a Hold rating and a price target of $38 (2 weeks ago). [TipRanks.com]( also reports that [Prothena Corporation plc]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $69.00 . The target pricing ranges from a high forecast of $94 down to a low forecast of $36. [Prothena Corporation plc (PRTA)](’s last closing price was $26.49 which would put the average price target at 160.48% upside. Here are 3rd party ratings for [PRTA](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 36% (89 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [AtriCure, Inc.]( Symbol: [ATRC]( Recent Price: $31.71 Average Analyst Price Target: $55.60 (75.34%) Market Cap: $1.50B Last Year's EPS: $-0.12 Consensus EPS Forecast: $-0.3 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Danielle Antalffy, analyst at UBS, reiterates coverage on [AtriCure, Inc. (ATRC)]( in the Healthcare sector with a Buy rating and a price target of $57 (3 weeks ago). [TipRanks.com]( also reports that [AtriCure, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $55.60 . The target pricing ranges from a high forecast of $65 down to a low forecast of $44. [AtriCure, Inc. (ATRC)](’s last closing price was $31.71 which would put the average price target at 75.34% upside. Here are 3rd party ratings for [ATRC](: - TipRanks.com: Buy - TradingView.com: Strong Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 35% (162 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Here’s The Secret “Profit Driver” Behind PLTR & NVDA & ????]( This is the secret force behind every major stock move in the last 110 years. It made NVDA stockholders into millionaires, and now there’s another chance to get in. [>> Watch now.]( --------------------------------------------------------------- [Palatin Technologies, Inc.]( Symbol: [PTN]( Recent Price: $3.95 Average Analyst Price Target: $43.00 (988.61%) Market Cap: $63.74M Last Year's EPS: $-0.91 Consensus EPS Forecast: $-0.75 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Joseph Pantginis, analyst at H.C. Wainwright, reiterates coverage on [Palatin Technologies, Inc. (PTN)]( in the Healthcare sector with a Buy rating and a price target of $70 (1 month ago). [TipRanks.com]( also reports that [Palatin Technologies, Inc.]( currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $43.00 . The target pricing ranges from a high forecast of $9 down to a low forecast of $50. [Palatin Technologies, Inc. (PTN)](’s last closing price was $3.95 which would put the average price target at 988.61% upside. Here are 3rd party ratings for [PTN](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Sell, Top 36% (89 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Karyopharm Therapeutics Inc.]( Symbol: [KPTI]( Recent Price: $1.29 Average Analyst Price Target: $5.75 (345.74%) Market Cap: $147.18M Last Year's EPS: $-0.29 Consensus EPS Forecast: $-0.28 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Brian Abrahams, analyst at RBC Capital, reiterates coverage on [Karyopharm Therapeutics Inc. (KPTI)]( in the Healthcare sector with a Buy rating and a price target of $3 (1 week ago). [TipRanks.com]( also reports that [Karyopharm Therapeutics Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $5.75 . The target pricing ranges from a high forecast of $5 down to a low forecast of $10. [Karyopharm Therapeutics Inc. (KPTI)](’s last closing price was $1.29 which would put the average price target at 345.74% upside. Here are 3rd party ratings for [KPTI](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Sell, Top 38% (96 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [The Strategic Gold Play You Haven't Heard About]( recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. [Get the full story on this overlooked gold investment strategy here.]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketTickerPress.com Market Ticker Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. By opening and/or clicking a link containted within this email, you are reconfirming your opt-in status. You can unsubscribe at any time. [If you are not a human, click here.]( MarketTickerPress.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | North Carolina | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software